Key Highlights

● The framing points to a plunge, but there is no identifiable public catalyst behind the quoted move.

● CNBX Pharmaceuticals, incorporated in Nevada with roots in Israel, has focused on cannabinoid-based cancer therapies, with a lead product it described as Cannabics SR, an oral capsule for advanced cancer patients.

● CNBX's quote sits at a fraction of a cent, leaving the company with a negligible market capitalisation, on the order of only a few thousand to a couple hundred thousand dollars, depending on the share count used, against roughly 1.6 billion shares outstanding.

● For a company in this condition, catalysts are hard to identify.

Company and Latest Development

CNBX Pharmaceuticals Inc (OTC:CNBX) CNBX Pharmaceuticals, incorporated in Nevada with roots in Israel, has focused on cannabinoid-based cancer therapies, with a lead product it described as Cannabics SR, an oral capsule for advanced cancer patients. The company adopted the CNBX name in 2022, having previously operated as Cannabics Pharmaceuticals and, earlier still, under unrelated shells named American Mining Corp and Thrust Energy Corp. Its most recent verified activity is regulatory rather than commercial: CNBX continues to file with the SEC, submitting a Quarterly Report on 24 June 2026 covering the period ended 31 May 2026, following its Annual Report late in 2025. Meaningful press announcements, however, appear to have dried up years ago.

What Is Driving Attention Around CNBX?

The framing points to a plunge, but there is no identifiable public catalyst behind the quoted move. At a price of roughly $0.000001, CNBX sits at the very bottom of the OTC market, where a single trade, or a data adjustment, can register as a huge percentage change. No company announcement supports a specific news-driven explanation. The most accurate characterisation is that CNBX is a near-dormant, deeply distressed OTC security whose price signals carry little fundamental information.

Key Numbers and Company Position

CNBX's quote sits at a fraction of a cent, leaving the company with a negligible market capitalisation, on the order of only a few thousand to a couple hundred thousand dollars, depending on the share count used, against roughly 1.6 billion shares outstanding. The stock is reported to have fallen close to 99% from its prior close and by a similar magnitude over the past year. The company remains an SEC-reporting entity with an August fiscal year-end, but it generates minimal disclosed operations, and its last substantive press release dates back to 2022.

What Could Come Next?

For a company in this condition, catalysts are hard to identify. Investors may be watching whether CNBX maintains its SEC reporting obligations, provides any update on its cannabinoid oncology research or the TaGeza Biopharma interest it acquired in 2022, or pursues a corporate transaction such as a Reverse merger or recapitalisation. Absent such steps, the security is likely to remain thinly traded and largely inactive.

Risks to Watch

The risks are extreme. CNBX is a sub-penny OTC stock with negligible market value, minimal Liquidity and scant recent disclosure, leaving it highly vulnerable to Volatility and speculative activity. There is significant risk that the company's research generates no commercial value, and holders face potential dilution, loss of reporting status, or a total loss. Verified, current information is very limited, which itself is a material risk for anyone attempting due diligence.

CNBX Pharmaceuticals Inc's Near-Term Catalysts Now Matter

CNBX Pharmaceuticals is a near-dormant, cannabinoid-focused cancer research company trading at effectively zero on the OTC market. Its dramatic quoted decline does not appear tied to any confirmed corporate event and is best explained by the mechanics of an Illiquid sub-penny security. Investors may be monitoring the company's continued SEC filings and any sign of renewed research, financing or strategic activity, while recognising that a stock in this state carries profound risk and offers very little reliable public information.